IGF-1 LR3 is a modified IGF-1 analog built to stay in circulation roughly 20 to 30 times longer than the native molecule. It binds IGF-1R directly and lights up the PI3K/Akt/mTOR pathway, the core route to protein synthesis and cellular repair. Worth saying plainly: no form of LR3 is FDA-approved and there is no human dosing data behind it.
- Built for staying power: LR3 persists roughly 20 to 30 times longer than native IGF-1, with a 20 to 30 hour half-life.researchdosing
- Binds IGF-1R with high affinity and activates PI3K/Akt/mTOR, the central protein-synthesis cascade.PubMed: IGF-1 LR3
- Signals directly at the receptor, bypassing the GH axis.peptidedosages
- Honest framing: LR3 is not FDA-approved in any form (mecasermin is a different molecule) and carries no human dosing data, so the entire evidence base is preclinical.PubMed: IGF-1 LR3
- Growth-signal caution runs both ways in the literature: breast, ovarian, or uterine history in female models, prostate signal in male models.thepeptidereport